Roundtable: Mitigating Immunogenicity Risks Factors In AAV Gene Therapy Clinical Trials

Keeping rAAV-based gene therapies safe for patients requires advanced companion diagnostics (CDx) and immunogenicity assessment. Tap into the insights from a panel discussion led by Citeline and featuring a speaker from Cerba Research. Explore rAAV’s current state, areas for improvement, regulatory challenges, and see what’s ahead for developers and lab services companies.

Read now to explore:

Risk factors in rAAV, especially immunogenicity-related challenges
Accurately assessing these immunogenicity risks with the right bioanalytical strategies
Bridging the gaps in rAAV in vitro and in vivo studies
Navigating challenges through laboratory services/developer partnerships
Planning ahead: what’s next for rAAV

Download the Roundtable summary

Your Company Email Address

Opt In?

By completing this form You agree Citeline and Cerba Research may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and Cerba Research.